A carregar...
Is chronic AhR activation by rapidly metabolized ligands safe for the treatment of immune-mediated diseases?
There is a long standing perception that AhR ligands are automatically disqualified from pharmaceutical development due to their induction of Cyp1a1 as well as their potential for causing “dioxin-like” toxicities. However, recent discoveries of new AhR ligands with potential therapeutic applications...
Na minha lista:
| Publicado no: | Curr Opin Toxicol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5607744/ https://ncbi.nlm.nih.gov/pubmed/28944315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cotox.2017.01.007 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|